BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
21 Incredibly Interesting Contemplations To Observe Consistently - 2As tetanus vaccination rates decline, doctors worry about rising case numbers
- 3Saudi Arabia says it intercepted 7 missiles, debris falls near energy facilities
- 4Explainer-What has happened to the damaged spacecraft at China's space station?
- 5Vote In favor of Your Favored Kind Of Bites
- Journey Lines for Each Explorer: Track down Your Ideal Journey
- A definitive Bike Standoff: Decision in favor of Your Number one Ride
- Find Serenity: 10 Stunning Setting up camp Areas
- How did birds survive while dinosaurs went extinct?
- 'Not the moon that I'm used to seeing': Artemis II astronauts describe seeing the far side
- Science is best communicated through identity and culture – how researchers are ensuring STEM serves their communities
- Vote in favor of Your #1 sort of pie
- Scientists uncover an ant assassination scheme that helps a parasitic queen rise to power
- Malaysian broadcaster rejects altered graphic about electricity rate hike
